Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial

Autor: Brendan N. Putko, Grayson Beecher, Zaeem A. Siddiqi

Publikováno v: Frontiers in Neurology, Vol 11 (2020)

Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels

Externí odkaz: https://doaj.org/article/8d995145b4cc47dcac1d0eb320221dfe

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

Autor: Michael Schroeter, Amgad Shebl, Leslie Roberts, Takuya Ohkubo, M. Chatzopoulos, Nan van Geloven, Robert D. Henderson, Catharina G. Faber, R. Talab, K. George, A. Kutschenko, E. Chi-Ho Lai, M. Bednar, Inna Rubanovits, Claudia Sommer, J. Oechtering, M. Tomiyama, Hans-Peter Hartung, Mari Auranen, G. Le Masson, Konrad Rejdak, Marina Grandis, Eroboghene E. Ubogu, Senda Ajroud-Driss, Tim Hagenacker, Lisa D. Hobson-Webb, Masayuki Baba, Khema Sharma, Miriam Freimer, Kazumasa Yokoyama, U. Chyrchel-Paszkiewicz, Karissa L. Gable, P. Van Damme, J. Zschuentzsch, I. N. van Schaik, S. Benitez, K. Nishiyama, J. Demeestere, Daniele Cazzato, F. Bethke, R. Carne, Gen Sobue, C. Marquez Infante, Norman Latov, David Walk, B. Murinson, Katrin Gross-Paju, Helmar C. Lehmann, M. Antonia, Ginna Gonzalez, M. Zibetti, Anne-Cécile Wielanek-Bachelet, Vera Bril, Stefania Morino, Mika Saarela, S. Mumfrey, Said R. Beydoun, Takanori Yokota, Maria Salvado, John T. Kissel, C. D'Amour, Ericka Simpson, D. Aufauvre, P. MacDonald, Orell Mielke, David R. Cornblath, Masahiro Iijima, Janneke G. J. Hoeijmakers, Nora A. Visser, Takashi Kanda, K. Kanai, Jeffrey A. Allen, Richard A. Lewis, Anne D. Sperfeld, J. Sussova, D. Mueller, A. Algom, Fabian Klostermann, I. Melamed, David Yarnitsky, J. Haas, Josep Gamez, A Schenone, P. Kunc, Ingemar S. J. Merkies, C. Trebst, F. Ciccocioppo, Ralf Gold, Vivian E. Drory, H. Onoue, Stefan Blum, P. Berlit, S. Muley, Tsugio Akutsu, T. Kalous, Michael P. Lunn, Alessandro Testori, Dale J. Lange, Giuseppe Lauria, D. Liebetanz, A. Jaspert-Grehl, Giovanni Antonini, Masahiro Mori, S. Larue, John-Philip Lawo, C. Goerlitz, H. Johl, M. Kawai, Nicolette C. Notermans, U. Sorro, R. Yoon, Daniela M. Menichella, T. Lavin, Billie L. Durn, J. Morrow, Richard J. Barohn, Dario Cocito, T. Rao, Martin Stangel, Satoshi Kuwabara, Jean Pouget, Emilien Delmont, David Gosal, Alexander Shtilbans, Sandro Sorbi, Florian Then Bergh, J. Schmidt, Shahram Attarian, Pierre Clavelou, Andreas Meisel, Sabrina Matà, Russell L. Chin, Mazen M. Dimachkie, Juliane Klehmet, K. Ohyama, Martin Vališ, Filip Eftimov, Shafeeq Ladha, A. Sabet, P. Baum, Claude Desnuelle, Kenichi Kaida, D. Kramer, Olaf Hoffmann, C. Casanovas Pons, A. Di Muzio, Ivo N. van Schaik, Toomas Toomsoo

Publikováno v: Journal of the peripheral nervous system, 24(1), 72-79. Wiley-Blackwell
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of the Peripheral Nervous System, 24(1), 72. Wiley-Blackwell
Journal of the Peripheral Nervous System

PATH study group.
In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7039eb5a61ad1011b5914f9a690d3c9c
https://pure.amc.nl/en/publications/restabilization-treatment-after-intravenous-immunoglobulin-withdrawal-in-chronic-inflammatory-demyelinating-polyneuropathy-results-from-the-prerandomization-phase-of-the-polyneuropathy-and-treatment-with-hizentra-study(a3597aa6-7290-41d2-9849-99a91b4daf0e).html

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency

Autor: Mikhail Rojavin, Jonathan M. Edelman, Jagdev S. Sidhu, Marc Pfister

Publikováno v: Biologics in Therapy

Introduction Standard treatment for patients with primary immunodeficiency (PID) is monthly intravenous immunoglobulin (IVIG), or weekly/biweekly subcutaneous immunoglobulin (SCIG) infusion. We used population pharmacokinetic modeling to predict immu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1011b7c8b3b3272aaa9c3acb50ab82a
http://europepmc.org/articles/PMC4254869

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.